Pulmonary Disease Clinical Trials

21 recruiting

Pulmonary Disease Trials at a Glance

283 actively recruiting trials for pulmonary disease are listed on ClinicalTrialsFinder across 6 cities in 64 countries. The largest study group is Not Applicable with 97 trials, with the heaviest enrollment activity in Beijing, London, and Miami. Lead sponsors running pulmonary disease studies include AstraZeneca, China-Japan Friendship Hospital, and Riphah International University.

Browse pulmonary disease trials by phase

Treatments under study

About Pulmonary Disease Clinical Trials

Looking for clinical trials for Pulmonary Disease? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pulmonary Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pulmonary Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 283 trials

Recruiting
Not Applicable

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

Chronic Obstructive Pulmonary DiseaseCOPD
Nuvaira, Inc.200 enrolled10 locationsNCT07051707
Recruiting
Not Applicable

Measurement of Viscoelastic Properties of Bronchopulmonary Secretions.

Obstructive Pulmonary Disease
Cliniques universitaires Saint-Luc- Université Catholique de Louvain500 enrolled1 locationNCT03888300
Recruiting

Study of Lung Proteins in Patients With Pneumonia

Pulmonary DiseasePneumoniaLung Disease
National Institutes of Health Clinical Center (CC)750 enrolled1 locationNCT00077909
Recruiting
Phase 4

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease
Sanofi218 enrolled58 locationsNCT07053423
Recruiting

Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo

Chronic Obstructive Pulmonary Disease
AstraZeneca1,400 enrolled21 locationsNCT07069829
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled188 locationsNCT07190222
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled166 locationsNCT07190209
Recruiting

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Chronic Obstructive Pulmonary Disease
AstraZeneca1,000 enrolled20 locationsNCT06862206
Recruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Pulmonary Disease, Chronic Obstructive
AstraZeneca2,000 enrolled7 locationsNCT06712563
Recruiting

Study of Patient With Frequent Exacerbations in Moscow

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca500 enrolled1 locationNCT07307781
Recruiting
Phase 1Phase 2

Feasibility of Semaglutide in Advanced Lung Disease

ObesityChronic Obstructive Pulmonary DiseaseInterstitial Lung Disease+2 more
University of Pennsylvania8 enrolled1 locationNCT05746039
Recruiting
Phase 2

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

Chronic Obstructive Pulmonary Disease
Verona Pharma plc480 enrolled55 locationsNCT07016412
Recruiting
Phase 2

Phase II Study of RC1416 Injection in COPD

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Nanjing RegeneCore Biotech Co., Ltd.180 enrolled41 locationsNCT07402551
Recruiting

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

Pulmonary Disease, Chronic ObstructiveExacerbation Copd
University Hospital, Grenoble240 enrolled2 locationsNCT05704881
Recruiting
Phase 4

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

Chronic Obstructive Pulmonary DiseaseHyperinflation
AstraZeneca56 enrolled7 locationsNCT07073950
Recruiting
Phase 1Phase 2

Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I/IIa

Chronic Obstructive Pulmonary Disease
University Hospital, Grenoble24 enrolled1 locationNCT04427826
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
Reistone Biopharma Company Limited237 enrolled1 locationNCT07349524
Recruiting

Eosinopenia in Severe COPD Exacerbation

Chronic Obstructive Pulmonary Disease
Northumbria Healthcare NHS Foundation Trust200 enrolled1 locationNCT06188065
Recruiting
Early Phase 1

Merck IIT: RRP Pembro and Lenvatinib

Pulmonary DiseaseRecurrent Respiratory PapillomatosisHuman Papilloma Virus
Yale University20 enrolled1 locationNCT04645602
Recruiting

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Pulmonary DiseasePulmonary Hypertension
National Institutes of Health Clinical Center (CC)270 enrolled1 locationNCT01730092